Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients with Myelofibrosis.

submitted by: mcgheekkm

Dr. Animesh Pardanani, Assistant Professor of Medicine and Consultant in the Division of Hematology at Mayo Clinic in Rochester, MN, Discusses his article, coauthored with Dr. Ayalew Tefferi, on potential complications from withdrawal of ruxolitinib. Available at: http://www.mayoclinicproceedings.com/content/early/recent.

Cannabinoids

submitted by: alex01
Daniele Piomelli, PhD. - Another approach was discussed by D. Piomelli (University of California, Irvine). URB 597, an inhibitor of fatty acid amide hydrolase (FAAH), is expected to increase anandamide signaling and is being currently clinically tested in the therapy of pain. An increase in anandamide signaling may also be useful in the therapy of depression. This is a novel approach to the development of antidepressants. The signaling can be enhanced by blocking anadamide metabolism or by...